BAYER AKTIENGESELLSCHAFT 4
4 · Pyxis Oncology, Inc. · Filed Oct 15, 2021
Insider Transaction Report
Form 4
Bayer World Investments B.V.
10% Owner
Transactions
- Conversion
Common Stock
2021-10-13+2,742,338→ 2,742,338 total - Conversion
Series A Convertible Preferred Stock
2021-10-13−11,362,462→ 0 total→ Common Stock (1,786,831 underlying) - Conversion
Series B Convertible Preferred Stock
2021-10-13−6,076,072→ 0 total→ Common Stock (955,507 underlying)
Footnotes (2)
- [F1]Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.
- [F2]The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.